VP Clin Dev & Med Affairs, DBV Technologies; Clin Assoc Prof, UPMC Children’s Hospital of Pittsburgh. Postings & opinions are my own and not DBV’s or UPMC’s.
We are excited to have our EPITOPE Phase 3 trial evaluating our investigational Viaskin Peanut in children 1-3 years published in The New England Journal of Medicine (@NEJM ). Watch below and read the publication here: https://t.co/y5v4oX2K8A
In the phase 3 EPITOPE trial involving children 1 to 3 years of age with peanut allergy, epicutaneous immunotherapy by means of a peanut patch was superior to placebo in desensitizing children to peanut. https://t.co/USk6HBI9Qh
#pediatrics
We’ve seen promising safety and efficacy data for the peanut patch in children and adolescents…
Great to see similar benefit in toddlers as well!
Hot off the press: https://t.co/x9JeUjwAoB
We're proud to share that @NEJM has published our EPITOPE Phase 3 trial evaluating our investigational Viaskin Peanut in #PeanutAllergic children 1-3 years. Learn more here: https://t.co/HlGjDG5q0q
We are pleased to announce FDA provided pre-BLA written response on regulatory path for Viaskin Peanut patch in 1-3 year olds with confirmed peanut allergy. Read more here: https://t.co/oTf5hcCEzP
We are excited to announce the first patient screened in our VITESSE Phase 3 clinical trial in #PeanutAllergic children 4-7 years old. Read more about our trial here: https://t.co/L6fWg6OZK1
The one and only Dr. Cox (aka @JohnCMcGinley 😆) does a great job in this video discussing how and why allergists can help👏
Love the awareness campaign by @ACAAI
https://t.co/CTw3LfPRFz
A new study in @JACIInPractice shows patients with #PeanutAllergy who receive care from an allergist experience significantly lower total mean costs than those who do not see a specialist.
https://t.co/tEEdux7N5g
Despite greater severity of disease, patients with peanut #allergy experience lower total mean health care costs than those with other food allergies, said researchers at @ChildrensColo. Also, @ruchisgupta of @cfaarnu shares her perspective. #foodallergy
https://t.co/WPSVGHhhDO
Despite greater severity of disease, patients with peanut #allergy experience lower total mean health care costs than those with other food allergies, said researchers at @ChildrensColo. Also, @ruchisgupta of @cfaarnu shares her perspective. #foodallergy
https://t.co/WPSVGHhhDO
Patients with peanut #allergy who receive care from an allergist experience significantly lower total mean costs than those who do not see a specialist, said researchers at @ChildrensColo. Also, @ruchisgupta of @NUFeinbergMed shares her perspective.
https://t.co/WPSVGGZ8pG
Read results from the Phase 3 REALISE trial studying the safety and tolerability of epicutaneous immunotherapy with investigational patch treatment in children, supporting its continued investigation as a new potential treatment option for peanut allergy. https://t.co/60bpA7Ikog